Investigational Site Number :0760002

São Paulo 04038-002

1 studies enrolling now · 3 studies all time

What they study most

Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Sphingomyelin Lipidosis, Type 1 Diabetes Mellitus

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD) — Completed
• Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus — Completed